Bipolar Bozukluk ve Parkinson Hastalığı Birlikteliğinde Farmakoterapi İkilemi: Bir Olgu Sunumu

Yıl 2021, Cilt: 12 Sayı: 2, 233 - 236, 20.08.2021

Bilal Tanrıtanır

Öz

Amaç: Bipolar bozukluk ile Parkinson hastalığının birlikteliğinde tedavilerinin birbirlerini olumsuz etkileyeceği bu nedenle kullanılan ajanların farmakodinamik etkilerine iyi düzeyde hakim olmanın tedavinin seyrini dolayısıyla hastanın iyilik halini ne ölçüde etkilediğini bir olgu üzerinden paylaşmak hedeflenmiştir.
Olgu: 66 yaşındaki Bipolar bozukluğu olan erkek bir hastanın komorbid Parkinson hastalığı ile birlikte depresyon, mani ve parkinsonizm üçgeninde her üç durumu da dengede tutacak tedavi düzenlenmesi sunulmuştur.
Sonuç: Dopamin agonisti ve antagonisti ajanların birlikte kullanılması etki ve yan etkiler açısından hassas bir denge gerektirmekte olup farmakodinamik etkilerin önemi tartışılmıştır.

Anahtar Kelimeler

bipolar, parkinson, pramipeksol

Destekleyen Kurum

Bulunmamakta

Proje Numarası

Bulunmamakta

Teşekkür

Bulunmamakta

Kaynakça

• 1. Schneider F, Althaus A, Backes V, Dodel R. Psychiatric symptoms in Parkinson’s disease.Eur Arch Psychiatry Clin Neurosci. 2008; 258 (Suppl 5):55-9.
• 2. Sajatovic M. Treatment of bipolar disorder in older adults. Int J Geriatr Psychiatry 2002; 17:865-73.
• 3. Sweet RA, Pollock BG. New atypical antipsychotics. Experience and utility in the elderly. Drugs Aging. 1998 Feb;12(2):115-27.
• 4. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999 Feb;60(2):107-15.
• 5. Gregory C, McKenna P. Pharmacological management of schizophrenia in older patients. Drugs Aging. 1994 Oct;5(4):254-62.
• 6. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q. 1992 Spring;63(1):51- 70. 7. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993 Jul 15;329(3):162-7.
• 8. Schuster P, Gabriel E, Küfferle B, Strobl G, Karobath M. Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol. 1977;10(4):437-41.
• 9. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996 Oct;47(4):1085-7.
• 10. Stover NP, Juncos JL. Olanzapine treatment of parkinsonian patients with psychosis. Neurology 1999; 52 (Suppl 2):A215
• 11. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55(6):789-94. 12. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997 Aug 15;42(4):233-46.
• 13. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997 Jun;54(6):549-57.
• 14. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. Seroquel Study Group. J Clin Psychopharmacol. 1996 Apr;16(2):158-69.
• 15. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997 Oct;96(4):265-73.
• 16. Stahl S.M. Stahl'ın Temel Psikofarmakolojisi. Uzbay T. Çeviri Editörü. İstanbul Tıp Kitabevi; 2012. s. 415.
• 17. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW, Chuang DM, Hong JS. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry. 2006 Dec;11(12):1116-25.
• 18. Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS, Rosenbaum JF, Fava M. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry. 2000 Sep;12(3):137-40.
• 19. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001 Jul;34(4):137-41.
• 20. Singh A, Althoff R, Martineau RJ, Jacobson J. Pramipexole, ropinirole, and mania in Parkinson's disease. Am J Psychiatry. 2005 Apr;162(4):814-5.
• 21. Sharma V, Smith A. A case of mania following the use of pramipexole. Am J Psychiatry. 2007 Feb;164(2):351.
• 22. Ulla M, Thobois S, Lemaire JJ, Schmitt A, Derost P, Broussolle E, Llorca PM, Durif F. Manic behaviour induced by deep-brain stimulation in Parkinson's disease: evidence of substantia nigra implication? J Neurol Neurosurg Psychiatry. 2006 Dec;77(12):1363-6